A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)-MedSci.cn

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Hospital, MA; Cluzeau, T; Garnier, A; Marconi, G; Tavernier, E; Thepot, S; Stamatoullas, A; Papayannidis, C; Park, S; Bigot, N; Selmi, LAS; Chermat, F; Chevret, S; Fenaux, P

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务